Safety and Efficacy of CMX-2043 for Protection of the Heart and Kidneys in Subjects Undergoing Coronary Angiography

Model scores of the 29,894 trials active now.

Model score 13% for any early termination, 2% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 20% of the time (389 trials).

Finished trial that started 2008–2014: scored by a model trained without any trial from its start year, so its own outcome was never used.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2015-12-31. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Sponsor's past termination rate: 0% (lowers risk) · Sponsor's track record
• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: coronarycardiacthe subjectacuteventricular
  Phrases that lowered it: safetyclinicalevaluatescreeningefficacy
• Accepts healthy volunteers: No (raises risk) · Who can join
• Design: single group (raises risk) · Design
• Blinding: quadruple (lowers risk) · Design
• Phase: 2 (raises risk) · Design
• Number of arms: 4 (lowers risk) · Design
• Drug's FAERS reports with a death: no FAERS history (raises risk) · Drug's FDA history
• Disease area, cancer: No (lowers risk) · Disease area
• Drug's FAERS reports marked serious: no FAERS history (raises risk) · Drug's FDA history
• Has a data monitoring committee: No (lowers risk) · Design
• Sponsor type: industry (lowers risk) · Sponsor's track record
• Trials the sponsor started in the prior 2 years: 0 (raises risk) · Sponsor's track record
• Minimum age: 18 (raises risk) · Who can join
• Disease area, cardiovascular: Yes (raises risk) · Disease area
• Maximum age: not given (lowers risk) · Who can join
• Keywords listed: 0 (raises risk) · Design
• Primary purpose: prevention (lowers risk) · Design
• Responsible party: sponsor (lowers risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Safety and Efficacy of CMX-2043 in Subjects Undergoing Coronary Reperfusion Therapy NCT00984802 · started 2010 · scored riskier than 20% of active trials completed
• Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI NCT05758896 · started 2023 · scored riskier than 71% of active trials completed
• Efficacy and Safety of MEDI6570 in Patients With a History of Myocardial Infarction NCT04610892 · started 2020 · scored riskier than 42% of active trials completed
• Safety of PZ-128 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention NCT02561000 · started 2016 · scored riskier than 89% of active trials completed
• ApoA-I Synthesis Stimulation and Intravascular Ultrasound for Coronary Atheroma Regression Evaluation NCT01067820 · started 2011 · scored riskier than 68% of active trials completed

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.